Diagnosed prevalent cases of Nontuberculous Mycobacteria (NTM) infections are expected to increase in the US, the UK, and Japan by 0.88% between 2021 and 2031.
Treatment regimens for NTM are a combination therapy of at least three different antibiotics, frequently including macrolides.
The greatest unmet needs within the NTM market are new antibiotics with improved success rates and minimal toxicity.
The late stage NTM pipeline consists of seven drugs, six of which are first in class therapies.
The NTM market in the US, the UK, and Japan was valued at $8.59 Billion in 2021. The market is projected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $11.04 Billion by 2031.
Treatment regimens for NTM are a combination therapy of at least three different antibiotics, frequently including macrolides.
The greatest unmet needs within the NTM market are new antibiotics with improved success rates and minimal toxicity.
The late stage NTM pipeline consists of seven drugs, six of which are first in class therapies.
The NTM market in the US, the UK, and Japan was valued at $8.59 Billion in 2021. The market is projected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $11.04 Billion by 2031.
Scope
- Overview of nontuberculous mycobacteria (NTM), its pathogenicity, manifestations, and types of infection.
- Epidemiology that looks into diagnosed incident and prevalent cases of NTM by sex and by 3MM.
- Overview of diagnostics and treatment, treatment profiles of combination therapy for different NTM strains.
- Quotes from three key opinion leaders (KOLs) from the 3MM.
- Key topics covered for nontuberculous mycobacteria drugs in the 3MM include trends, pipeline and market analysis, opportunities, challenges, and unmet needs.
- Pipeline assessment: emerging novel trends under development, and analysis of the most promising late-stage NTM pipeline drugs in clinical development.
- Analysis of the key dynamics of the nontuberculous mycobacteria drugs market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight potential business opportunities.
Reasons to Buy
- What impact will late-stage pipeline agents have on the market? Which class of NTM drugs will have the highest peak sales, and why?
- What country in the 3MM will experience the most growth, and why?
- What are the current unmet needs and which pipeline drugs or strategies are positioned to counter these unmet needs? What are the opportunities for R&D in the NTM space?
- How is the field of NTM therapies going to move forward?
- What is the current and future outlook for NTM therapeutics according to KOLs?
Table of Contents
1 Executive Summary10 Contact Us
2 Disease Overview
3 Epidemiology
4 Current Treatment Options
5 Unmet Needs and Opportunities
6 Pipeline Assessment
7 R&D Strategies
8 Market Outlook
9 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Revimmune Inc
- Novartis AG
- Insmed Inc
- Nobelpharma Co Ltd
- Paratek Pharmaceuticals Inc
- Revimmune LLC
- RedHill Biopharma Ltd
- RevImmune SAS
- Insmed Ltd
